curcumin and J147

curcumin has been researched along with J147* in 9 studies

Reviews

2 review(s) available for curcumin and J147

ArticleYear
Current evidence for J147 as a potential therapeutic agent in nervous system disease: a narrative review.
    BMC neurology, 2023, Sep-06, Volume: 23, Issue:1

    Curcumin has anti-inflammatory, antioxidant, and anticancer effects and is used to treat diseases such as dermatological diseases, infection, stress, depression, and anxiety. J147, an analogue of curcumin, is designed and synthesized with better stability and bioavailability. Accumulating evidence demonstrates the potential role of J147 in the prevention and treatment of Alzheimer's disease, diabetic neuropathy, ischemic stroke, depression, anxiety, and fatty liver disease. In this narrative review, we summarized the background and biochemical properties of J147 and discussed the role and mechanism of J147 in different diseases. Overall, the mechanical attributes of J147 connote it as a potential target for the prevention and treatment of neurological diseases.

    Topics: Anxiety; Anxiety Disorders; Curcumin; Diabetic Neuropathies; Humans

2023
ATP synthase and Alzheimer's disease: putting a spin on the mitochondrial hypothesis.
    Aging, 2020, 08-27, Volume: 12, Issue:16

    It is estimated that over 44 million people across the globe have dementia, and half of these cases are believed to be Alzheimer's disease (AD). As the proportion of the global population which is over the age 60 increases so will the number of individuals living with AD. This will result in ever-increasing demands on healthcare systems and the economy. AD can be either sporadic or familial, but both present with similar pathobiology and symptoms. Three prominent theories about the cause of AD are the amyloid, tau and mitochondrial hypotheses. The mitochondrial hypothesis focuses on mitochondrial dysfunction in AD, however little attention has been given to the potential dysfunction of the mitochondrial ATP synthase in AD. ATP synthase is a proton pump which harnesses the chemical potential energy of the proton gradient across the inner mitochondrial membrane (IMM), generated by the electron transport chain (ETC), in order to produce the cellular energy currency ATP. This review presents the evidence accumulated so far that demonstrates dysfunction of ATP synthase in AD, before highlighting two potential pharmacological interventions which may modulate ATP synthase.

    Topics: Alzheimer Disease; Animals; Benzofurans; Brain; Curcumin; Energy Metabolism; Humans; Mitochondria; Mitochondrial Proton-Translocating ATPases; Neuroprotective Agents

2020

Other Studies

7 other study(ies) available for curcumin and J147

ArticleYear
The Alzheimer's disease drug candidate J147 decreases blood plasma fatty acid levels via modulation of AMPK/ACC1 signaling in the liver.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022, Volume: 147

    J147 is a novel drug candidate developed to treat neurological dysfunction. Numerous studies have demonstrated the beneficial effects of J147 in cellular and animal models of disease which has led to the transitioning of the compound into human clinical trials. However, no biomarkers for its target engagement have been identified. Here, we determined if specific metabolites in the plasma could be indicative of J147's activity in vivo. Plasma lipidomics data from three independent rodent studies were assessed along with liver lipidomics data from one of the studies. J147 consistently reduced plasma free fatty acid (FFA) levels across the independent studies. Decreased FFA levels were also found in the livers of J147-treated mice that correlated well with those in the plasma. These changes in the liver were associated with activation of the AMP-activated protein kinase/acetyl-CoA carboxylase 1 signaling pathway. A reduction in FFA levels by J147 was confirmed in HepG2 cells, where activation of the AMPK/ACC1 pathway was seen along with increases in acetyl-CoA and ATP levels which correlated with enhanced cellular bioenergetics. Our data show that J147 targets liver cells to activate the AMPK/ACC1 signaling pathway and preserve energy at the expense of inhibiting FFA synthesis.

    Topics: Acetyltransferases; Alzheimer Disease; AMP-Activated Protein Kinases; Animals; Curcumin; Fatty Acids, Nonesterified; Female; Hep G2 Cells; Humans; Lipid Metabolism; Liver; Male; Mice; Rats; Rats, Wistar; Signal Transduction

2022
Geroprotective effects of Alzheimer's disease drug candidates.
    Aging, 2021, 02-06, Volume: 13, Issue:3

    Geroprotectors are compounds that slow the biological aging process in model organisms and may therefore extend healthy lifespan in humans. It is hypothesized that they do so by preserving the more youthful function of multiple organ systems. However, this hypothesis has rarely been tested in any organisms besides

    Topics: Aging; Alzheimer Disease; Animals; Brain; Caenorhabditis elegans; Curcumin; Disease Models, Animal; Drosophila melanogaster; Female; Kidney; Male; Mice; Protective Agents; Renal Insufficiency, Chronic

2021
Activation of monoaminergic system contributes to the antidepressant- and anxiolytic-like effects of J147.
    Behavioural brain research, 2021, 08-06, Volume: 411

    Major depressive disorder (MDD) is a severe mental disorder, which is closely related to the deficiency of monoamine neurotransmitters. Our previous study suggested that acute treatment with J147, a novel curcumin derivative, produced antidepressant-like effects in mouse model of depression by regulation of 5-HT receptor subtypes. However, it is still unknown whether the antidepressant-like effects of J147 are involved in activation of central monoaminergic system. In this study, a series of classical behavior tests were employed to assess the involvement of monoaminergic system in antidepressant- and anxiolytic-like effects after sub-acute treatment of mice with J147 for 3 days. The results suggested that J147 at 10 mg/kg significantly reduced the immobility time in both the tail suspension and forced swimming tests, but didn't show effects in the sucrose preference test. Similarly, sub-acute treatment of J147 did not induce amelioration in novelty suppressed feeding test. J147 increased duration and crossing time in the central area, but did not show significant change in rearing counts in the open field test. In neurochemical assays, studies suggested that serotonin and noradrenaline levels were significantly increased in the frontal cortex and hippocampus after treatment of J147 by the high-performance liquid chromatography (HPLC) with an electrochemical detector. Moreover, J147-induced significant inhibition of monoamine oxidase A activity. These findings suggest that the antidepressant- and anxiolytic-like effects of J147 might be related to the monoaminergic system by the evidence that high dose of J147 inhibits monoamine oxidase (MAO)-A activity and increases synaptic monoamines in the mouse brain.

    Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Behavior, Animal; Biogenic Monoamines; Curcumin; Depression; Depressive Disorder, Major; Disease Models, Animal; Frontal Lobe; Hippocampus; Male; Mice; Mice, Inbred ICR; Monoamine Oxidase; Motor Activity; Norepinephrine; Serotonin

2021
In Silico Repurposing of J147 for Neonatal Encephalopathy Treatment: Exploring Molecular Mechanisms of Mutant Mitochondrial ATP Synthase.
    Current pharmaceutical biotechnology, 2020, Volume: 21, Issue:14

    Neonatal Encephalopathy (NE) is a mitochondrial ATP synthase (mATPase) disease, which results in the death of infants. The case presented here is reportedly caused by complex V deficiency as a result of mutation of Arginine to Cysteine at residue 329 in the mATPase. A recent breakthrough was the discovery of J147, which targets mATPase in the treatment of Alzheimer's disease. Based on the concepts of computational target-based drug design, this study investigated the possibility of employing J147 as a viable candidate in the treatment of NE.. The structural dynamic implications of this drug on the mutated enzyme are yet to be elucidated. Hence, integrative molecular dynamics simulations and thermodynamic calculations were employed to investigate the activity of J147 on the mutated enzyme in comparison to its already established inhibitory activity on the wild-type enzyme.. A correlated structural trend occurred between the wild-type and mutant systems whereby all the systems exhibited an overall conformational transition. Equal observations in favorable free binding energies further substantiated uniformity in the mobility, and residual fluctuation of the wild-type and mutant systems. The similarity in the binding landscape suggests that J147 could as well modulate mutant mATPase activity in addition to causing structural modifications in the wild-type enzyme.. Findings suggest that J147 can stabilize the mutant protein and restore it to a similar structural state as the wild-type which depicts functionality. These details could be employed in drug design for potential drug resistance cases due to mATPase mutations that may present in the future.

    Topics: Allosteric Regulation; Brain Diseases; Computational Biology; Computer Simulation; Curcumin; Drug Design; Drug Repositioning; Genetic Diseases, Inborn; Humans; Mitochondria; Mitochondrial Proton-Translocating ATPases; Molecular Dynamics Simulation; Mutation

2020
Elevating acetyl-CoA levels reduces aspects of brain aging.
    eLife, 2019, 11-19, Volume: 8

    Because old age is the greatest risk factor for dementia, a successful therapy will require an understanding of the physiological changes that occur in the brain with aging. Here, two structurally distinct Alzheimer's disease (AD) drug candidates, CMS121 and J147, were used to identify a unique molecular pathway that is shared between the aging brain and AD. CMS121 and J147 reduced cognitive decline as well as metabolic and transcriptional markers of aging in the brain when administered to rapidly aging SAMP8 mice. Both compounds preserved mitochondrial homeostasis by regulating acetyl-coenzyme A (acetyl-CoA) metabolism. CMS121 and J147 increased the levels of acetyl-CoA in cell culture and mice via the inhibition of acetyl-CoA carboxylase 1 (ACC1), resulting in neuroprotection and increased acetylation of histone H3K9 in SAMP8 mice, a site linked to memory enhancement. These data show that targeting specific metabolic aspects of the aging brain could result in treatments for dementia.

    Topics: Acetyl Coenzyme A; Acetyl-CoA Carboxylase; Acetylation; Aging; Alzheimer Disease; Animals; Brain; Curcumin; Humans; Memory; Mice; Mitochondria; Protein Processing, Post-Translational; Signal Transduction

2019
The structure of the anti-aging agent J147 used for treating Alzheimer's disease.
    Acta crystallographica. Section C, Structural chemistry, 2019, 03-01, Volume: 75, Issue:Pt 3

    The molecular structure of the anti-aging agent J147 [systematic name: (E)-N-(2,4-dimethylphenyl)-2,2,2-trifluoro-N'-(3-methoxybenzylidene)acetohydrazide], C

    Topics: Curcumin; Density Functional Theory; Models, Chemical; Molecular Conformation; Neuroprotective Agents

2019
Deciphering the 'Elixir of Life': Dynamic Perspectives into the Allosteric Modulation of Mitochondrial ATP Synthase by J147, a Novel Drug in the Treatment of Alzheimer's Disease.
    Chemistry & biodiversity, 2019, Volume: 16, Issue:6

    The discovery of J147 represented a significant milestone in the treatment of age-related disorders, which was further augmented by the recent identification of mitochondrial ATP synthase as the therapeutic target. However, the underlying molecular events associated with the modulatory activity of J147 have remained unresolved till date. Herein, we present, for the first time, a dynamical approach to investigate the allosteric regulation of mATP synthase by J147, using a reliable human αγβ protein model. The highlight of our findings is the existence of the J147-bound protein in distinct structural associations at different MD simulation periods coupled with concurrent open↔close transitions of the β catalytic and α allosteric (ATP5A) sites as defined by Cα distances (d), TriCα (Θ) and dihedral (φ) angular parameters. Firstly, there was an initial pairing of the αγ subunits away from the β subunit followed by the formation of the 'non-catalytic' αβ pair at a distance from the γ subunit. Interestingly, J147-induced structural arrangements were accompanied by the systematic transition of the β catalytic site from a closed to an open state, while there was a concurrent transition of the allosteric site from an open α

    Topics: Allosteric Regulation; Alzheimer Disease; Binding Sites; Catalytic Domain; Curcumin; Humans; Hydrazines; Mitochondria; Mitochondrial Proton-Translocating ATPases; Molecular Docking Simulation; Principal Component Analysis; Static Electricity; Thermodynamics

2019